ClinicalTrials.gg
CompletedNCT04770038SANITYUpdated Mar 8, 2023

Social Integration During Psychiatric Inpatient Therapy as Predictor of Treatment Response

An observational study in Borderline Personality Disorder (BPD), sponsored by University of Oldenburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-08.

Sponsored by University of Oldenburg · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
87
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Borderline Personality Disorder with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Borderline Personality Disorder · Germany.

Started
2021
with 3 others
Observational
9 of 37
1 open now
Registered
22nd of 37
by date
Lead sponsor
2 of 37
University of Oldenburg

Among the 37 studies in Borderline Personality Disorder with a site in Germany, this one is one of 4 that started in 2021, is one of 9 observational ones, and was the 22nd registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

6 of the 37 studies in Borderline Personality Disorder with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Borderline Personality Disorder with a site in Germany, or all of them as a file.
02

Study summary

The present longitudinal study aims at (i) identifying neurobiological mechanisms associated with successful social integration during the treatment of inpatients with Borderline Personality Disorder (BPD) and (ii) improving biomarker-based predictions of treatment response by incorporating core metrics of social integration.

Read the detailed description

Social connections have a strong impact on mental and physical health. Surprisingly, however, there is a paucity of studies probing the predictive validity of perceived social connections such as subjective social support and loneliness for the outcomes of inpatient treatment of BPD. Although social impairments are key features of BPD psychopathology, social integration has been largely neglected, which may therefore explain the minimal translation of predictive molecular or imaging-based biomarkers into the clinic. The investigators hypothesize that the assessment of negative cognitive biases at baseline will help to identify BPD patients who will experience less social support and more loneliness during inpatient treatment. Furthermore, an inclusion of social integration indices may increase the incremental validity for the biomarker-based prediction of treatment response.

In this longitudinal, observational study, data from 56 BPD patients will be analyzed to assess negative cognitive biases and the underlying neurobiological mechanisms with behavioral, neuroendocrine, psychophysiological, and neural readouts before and after one month of inpatient Dialectical Behavior Therapy (DBT). To evaluate pathological biases, the patients' data will be compared with a control group of 31 healthy participants who will also be tested twice. Neural readouts include structural and functional magnetic resonance imaging (fMRI) measurements. The fMRI tasks will probe the processing of social touch, interpersonal trust, and interoception. To further investigate pathological distortions of social touch and interoception, interoceptive accuracy and comfort zones of social touch will be assessed. Further, patients and healthy participants will perform a positive social interaction task, accompanied by psychophysiological and neuroendocrinological measures. Psychometric questionnaires and semi-structured interviews will be used to monitor symptom load and social indices before, during, and after the inpatient treatment. Long-term effects will be assessed by questionnaires and interviews 8 and 20 weeks after inpatient treatment/waiting time, as well as after each DBT module (follow-ups). The investigators plan to conduct uni- and multivariate analyses of the baseline measurements to predict patients' social integration and treatment response during the inpatient therapy and examine treatment-related changes. The findings of this project may help identify vulnerable patients that benefit from adjunct therapies targeting negative social biases and improve biomarker-based models of treatment prediction.

03

Conditions studied

  • Borderline Personality Disorder (BPD)

Keywords

  • social integration
  • Borderline Personality Disorder
  • treatment response
  • psychiatric inpatient treatment
  • fMRI
  • negative social bias
  • social touch
  • interoception
  • trust
  • Dialectical Behavior Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Group 1: BPD patients are recruited from a waiting list for DBT inpatient treatment and directly during inpatient treatment at the University Clinic for Psychiatry and Psychotherapy, Karl-Jaspers-Klinik, Bad Zwischenahn, Germany.

Group 2: Healthy participants are recruited via the notice board of the University of Oldenburg, and, in order to achieve a more heterogenous sample, via online advertisments

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness / ability to give written to participate in the study
  • BPD patients: on a waiting list for DBT, BPD as primary diagnosis
  • Healthy participants: free of current physical or psychiatric illness
  • Fluent in German

Exclusion criteria

Exclusion Criteria:

  • for MRI investigation (e.g. agoraphobia, pacemaker, pregnancy)
  • Acute suicidality, current substance dependence or primary psychotic disorder
  • A history of head trauma or neurological illness
  • Scars on a predefined skin area (approx. 20 cm) of the shins
  • Healthy participants: current or past psychiatric inpatient treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
87 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patient Group

    56 BPD patients

    Behavioral: Dialectical Behavior Therapy (DBT)

  • Control Group

    31 Healthy participants

Interventions

  • BehavioralDialectical Behavior Therapy (DBT)

    Evidence-based psychotherapy for the treatment of Borderline Personality Disorder

06

What researchers measure

Primary outcomes

  1. Social integration during inpatient treatment as measured by questionnaires and interviews

    Social integration will be assessed with questionnaires and interviews (e.g. the perceived social support questionnaire).

    Time frame: Social integration (duration approx. 30-45 minutes) will be measured continuously during inpatient treatment (twice a week for four weeks).

  2. Changes in neural responses to interpersonal touch

    Blood-oxygen-level-dependent (BOLD) signal will be assessed while participants undergo a social touch task. Conditions consist of four types of touch trials with combinations of slow (\~ 5 cm/s) and fast touch (\~ 20 cm/s), as well as social (administered by hand) and non-social (administered with a brush) touch and a control (no touch) condition. An experimenter, who cannot be seen by the participant, will administer the touch across 20 cm of the shins. After each trial, participants will be asked to rate how comforting the touch was perceived. The neural responses to interpersonal touch will be compared before and after DBT-treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The fMRI task (duration approx. 15 minutes) will be performed before and after one month of inpatient DBT/waiting time.

  3. Changes in comfort ratings of interpersonal touch in the fMRI task

    During the social touch fMRI task, participants rate the comfort of the trial on a Visual Analogue Scale (VAS). The behavioral data will be analyzed and linked to the BOLD signal. Comfort ratings will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The fMRI task (duration approx. 15 minutes) will be performed before and after one month of inpatient DBT/waiting time.

  4. Changes in neural responses in the Trust Game

    BOLD signal will be measured while participants play a single-round trust game in the role of an investor. Participants will have to decide how much money they want to invest in an unknown trustee without receiving feedback about the decisions of the trustees. In a control condition, participants will play a risk game and invest money in a computer, which will randomly decide whether the money will be shared. The neural correlates will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The fMRI task (duration approx. 6 minutes) will be performed before and after one month of inpatient DBT/waiting time.

  5. Changes in interpersonal trust

    During the fMRI Trust Game, participants will decide how much (from 1 Euro to 10 Euro) they want to invest in the unknown trustees on a VAS. Furthermore, participants will rate the facial trustworthiness of the face stimuli used in the fMRI Trust Game. These behavioral data will be analyzed and linked to the BOLD signal. The behavioral data will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The fMRI task (duration approx. 6 minutes) will be performed before and after one month of inpatient DBT /waiting time.

  6. Changes in neural responses during an interoception task

    During the interoception fMRI task, participants are instructed to focus on their heart, their stomach, or color changes of the word "target" (as control). After every second trial, participants rate how intensely they perceived their heart or their stomach. During the control condition, participants indicate how intensely they perceived the color change. The neural correlates will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The fMRI task (duration approx. 13 minutes) will be performed before and after one month of inpatient DBT/waiting time.

  7. Changes in intensity ratings of bodily awareness in the fMRI task

    During the interoception fMRI task, participants rate how intensely they perceived their heart or their stomach on VAS. The behavioral data will be analyzed and linked to the BOLD signal. Intensity ratings will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The fMRI task (duration approx. 13 minutes) will be performed before and after one month of inpatient DBT/waiting time.

  8. Changes in interoceptive accuracy as measured by a heartbeat discrimination task

    During the heartbeat discrimination task, participants have to indicate, whether a series of tones is presented synchronously or asynchronously to their own heartbeat. In addition, they rate their confidence on their own assessment on a VAS. Interoceptive accuracy will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Interoceptive accuracy (duration approx. 20 minutes) will be assessed before and after one month of inpatient DBT/waiting time.

  9. Changes in interoceptive sensibility as measured with a questionnaire

    The Multidimensional Assessment of Interoceptive Awareness (MAIA-2) will be used to measure self-reported interoceptive sensibility. Questionnaire scores will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Interoceptive sensibility (duration approx. 5 minutes) will be measured before and after one month of inpatient DBT/waiting time.

  10. Changes in psychophysiological measures during a positive social interaction

    The positive social interaction will consist of a semi-structured ten-minute conversation between the participant and a same-sex unfamiliar experimenter. After a baseline measurement of five minutes, participants will talk about plans for a fictive lottery win and hobbies and interests. During the baseline, as well as during the conversation, psychophysiological parameters of both, the participant and the experimenter, will be measured simultaneously.

    Time frame: The positive social interaction (duration approx. 15 minutes) will be conducted before one month of inpatient DBT/waiting time

  11. Changes in hormone and enzyme salivary concentrations in response to a positive social interaction

    Saliva samples will be collected before, immediately after, and 15 minutes after the social interaction task.

    Time frame: The positive social interaction (duration approx. 15 minutes) will be conducted before one month of inpatient DBT/waiting time

  12. Changes in mood in response to a social interaction

    Mood state will be assessed with questionnaires (e.g. the Profile of Mood States (POMS)).

    Time frame: The positive social interaction (duration approx. 15 minutes) will be conducted before one month of inpatient DBT/waiting time

  13. Changes in bodily maps of social touch

    In a computerized task, participants will indicate on a human silhouette, where a specific person (e.g. their mother) would be allowed to touch them in everyday situations. Comfort zones of social touch for different members of their social network (e.g. brother, female stranger etc.) will be analyzed. Bodily maps will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: The bodily maps (duration approx. 10-15 minutes) will be assessed before and after 4-weeks DBT treatment/waiting time.

  14. Changes in attitude towards social touch

    The attitude towards social touch will be measured by the Social Touch Questionnaire (STQ). Self-reported touch preferences will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Self-reported touch preferences (duration approx. 5 minutes) will be assessed before and after one month of inpatient DBT/waiting time as well as during follow-up measurements.

  15. Changes in negative social biases

    Negative social biases will be assessed with questionnaires (e.g. the University of California Los Angeles (UCLA) Loneliness Scale). Questionnaire scores will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Questionnaires (duration approx. 15-20 minutes) will be measured before and after one month of inpatient DBT/waiting time as well as during follow-up measurements.

  16. Changes in symptom load

    Symptom load will be assessed with questionnaires and interviews (e.g. the Borderline-Symptom-List-23 (BSL-23)). Symptom load will be compared before and after the DBT treatment and will be measured continuously during DBT treatment.

    Time frame: Symptom load (duration approx. 30-45 minutes) will be measured before and after one month of inpatient DBT, continuously during therapy (twice a week for four weeks) as well as during follow-up measurements.

Secondary outcomes

  1. Changes in neural activity at resting state

    fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open. Participants will be instructed to look at a fixation cross for \~ 10 minutes. The neural correlates will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Resting State (duration approx. 10 minutes) will be performed before and after one month of inpatient DBT/waiting time.

  2. Changes in vigilance

    Vigilance will measured with the Psychomotor Vigilance Task (PVT). The PVT is a reaction time task in which participants respond to visual stimuli via button presses. Participants fixate a black screen and press a button as soon as a digital clock with a running time-measurement appears on screen. Vigilance will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Vigilance (duration approx. 5 minutes) will be measured one week before and after one month of inptatient DBT/waiting time.

  3. Childhood maltreatment

    The Childhood Trauma Questionnaire (CTQ) will be used to measure childhood maltreatment. The scale ranges between 5 and 100 points and higher scores indicate higher childhood maltreatment.

    Time frame: The CTQ (duration approx. 5 minutes) will be performed before one month of inpatient DBT/waiting time.

  4. Changes in symptom load of possible comorbidities

    Symptom load will be assessed with questionnaires (e.g. the Becks-Depression-Inventory-II (BDI-II)). Questionnaire scores will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Symptom load (duration approx. 10 minutes) will be measured before and after one month of inpatient DBT treatment/waiting time as well as during follow-up measurements.

  5. Changes in personality traits

    The big five personality traits will be measured with the NEO-Five-Factor-Inventory (NEO-FFI). Personality traits will be compared before and after the DBT treatment and the treatment-induced changes will be compared with changes in the healthy control group.

    Time frame: Personality traits (duration approx. 10 minutes) will be measured before and after one month of inpatient DBT/waiting time.

  6. Psychotherapy outcome as measured with a questionnaire

    Psychotherapy outcome will be assessed with the Bochum Change Questionnaire 2000 (BCQ-2000).

    Time frame: Psychotherapy outcome (duration approx. 5 minutes) will be measured after one month of inpatient DBT.

  7. Verbal intelligence

    Verbal intelligence will be measured with the Multiple Choice Vocabulary Test (MWT-B).

    Time frame: Verbal intelligence (duration approx. 5 minutes) will be measured before one month of inpatient DBT/waiting time.

07

Study locations

1 site
  • Department of Psychiatry, University of Oldenburg, Karl-Jaspers-Klinik
    Bad Zwischenahn, 26160, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2023, 23 months.

Of 19 observational studies under Borderline Personality Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 119. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 25, 2021
StartActual
Feb 10, 2021
Primary completionActual
Jan 21, 2023
CompletionActual
Jan 21, 2023
Last update
Mar 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04770038
Lead sponsor
University of Oldenburg
Collaborators
Prof. René Hurlemann, Jella Voelter, M.Sc.
Responsible party
Dirk Scheele (Prof., Ruhr University of Bochum) — Principal investigator
First posted
Feb 25, 2021
Start date
Feb 10, 2021
Primary completion
Jan 21, 2023
Completion
Jan 21, 2023
Last update
Mar 8, 2023

Study contacts

Dirk Scheele, Prof.
principal investigator · Ruhr University of Bochum, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion